DxS, Boehringer Ingelheim Partner on Companion Dx | GenomeWeb

NEW YORK (GenomeWeb News) - DxS is collaborating with Boehringer Ingelheim to develop a companion diagnostic test kit for the pharmaceutical company's BIBW 2992 (Tovok) drug candidate to identify mutations of the epidermal growth factor receptor in patients with non small cell lung cancer.

Manchester, UK-based DxS said that its EGFR companion diagnostic is a real-time PCR assay that is designed to detect the most common mutations in the EGFR gene. It said that the assay would be ready later this summer for use in Boehringer Ingelheim's phase III study of BIBW 2992.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.